BioSpace News Archive

Kronos Bio, Inc., dedicated to the development of first-in-class therapies that modulate historically undruggable targets, announced today that it has appointed Wes Trotter, Ph.D., as Vice President, Chemistry.

Candel Therapeutics, a leader in developing viral immunotherapies across multiple tumor indications, announced today that it has acquired all oncolytic and other Herpes Simplex Virus (HSV) based assets from PeriphaGen, Inc., bringing its vector engineering, production expertise and next-generation HSV drug development platform in-house.

Lab1636 commits to advance certain Harvard innovations toward a possible therapeutic for tactile hypersensitivity experienced in autism spectrum disorders

Certara®, the global model-informed drug development and decision support leader, today announced that its Simcyp® Population-based Simulator was used to support Galderma’s successful U.S. Food and Drug Administration (FDA) new drug application (NDA) for AKLIEF (trifarotene) Cream, 0.005%

Tarveda Therapeutics, Inc. announced that Drew Fromkin, President and Chief Executive Officer, will present at the 2020 Biotech Showcase, occurring January 13-15, 2020 at the Hilton Union Square in San Francisco, CA.

Xencor, Inc. announced it has entered into a technology license agreement in which Gilead Sciences, Inc., will access Xencor’s Xtend™ extended half-life and Cytotoxic XmAb® Fc technologies for developing and commercializing GS-9722, Gilead’s first-in-class effector-enhanced broadly neutralizing anti-HIV antibody, which is currently in Phase 1 clinical development.

The conference will be held at the Westin St. Francis in San Francisco, CA.

Altavant plans to develop OSP-101 for the treatment of bronchiolitis obliterans syndrome, the leading cause of morbidity and mortality in post-lung transplant patients

Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced that it will make a presentation at the 38th Annual J.P. Morgan Healthcare Conference.

Ms. Azmat will lead identification, evaluation and execution of new business development opportunities and development of the company’s corporate growth strategy.